Frequently Ask Question

While we have only done limited testing for events diabetics, we believe Auxulin should reduce the magnitude and duration of events hyperglycemic events, especially for those events who use insulin

Yes

Though we didn’t run a robust clinical trial testing Auxulin’s impact on A1C percentages, we measured the hemoglobin A1C levels for Tommy and Gary (Auxulin's founders) who consistently took the product over a period of several months. Over a 4-to-6-month period, they experienced an average A1C percentage reduction of nearly 0.1 percent per month. Tommy and Gary's A1C percentages have remained at lifelong lows.